

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1-34. (Canceled)

35. (Previously presented) The method of claim 49, wherein said antibody or a fragment thereof binds SEQ ID NO:1 or 2.

36-48. (Canceled)

49. (Currently Amended) A method of inhibiting or attenuating differentiation of Th0 cells into a Th2 subtype, comprising administering to the Th0 cells an effective amount of a TCCR (SEQ ID NO:1) agonist antibody, ~~or TCCR binding fragment thereof~~ a bispecific TCCR (SEQ ID NO:1) agonist antibody, a heteroconjugate TCCR (SEQ ID NO:1) agonist antibody, a TCCR (SEQ ID NO:1) agonist diabody, or a fragment of a TCCR (SEQ ID NO:1) agonist antibody comprising two or more TCCR antigen binding sites.

50. (Previously Presented) The method of claim 49, wherein the inhibiting or attenuating occurs in a mammal.

51-56. (Canceled)

57. (Previously Presented) The method of claim 35, wherein the antibody is a monoclonal antibody.

58. (Previously Presented) The method of claim 35, wherein the antibody is a humanized antibody.

59. (Currently Amended) The method of claim 35, wherein the antibody fragment is a ~~Fab, Fab'~~, F(ab')<sub>2</sub>, Fv, single-chain antibody, or a diabody.

60-68. (Canceled)